Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer

Mouri, Atsuto; Kaira, Kyoichi; Shiono, Ayako; Yamaguchi, Ou; Murayama, Yoshitake; Kobayashi, Kunihiko; Kagamu, Hiroshi

doi:10.1111/1759-7714.13022

Cited by 12 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, in the JVCG trial, patients aged 75 years and older were rarely enrolled, resulting in a lack of clinical trial data for older patients. In recent retrospective studies which included some patients aged 75 years and older treated with RAM+DOC, there were no instances of FN after receiving prophylactic PEG‐G‐CSF support, whereas FN developed in patients not receiving PEG‐G‐CSF . In consideration of our results, the administration of PEG‐G‐CSF seemed to be essential therapy for RAM+DOC, especially in older patients.…”

Section: Discussionsupporting

confidence: 53%

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Background: Ramucirumab plus docetaxel (RAM+DOC) is expected to prolong survival in patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy and safety for older patients remains unknown. The objective of this study was to evaluate the efficacy and safety of RAM+DOC in patients 75 years and older. Methods: We retrospectively reviewed consecutive patients with advanced NSCLC who had received RAM+DOC treatment at three institutions. We compared the efficacy and safety in patients 75 years and older to those under 75 years of age. Results: A total of 114 patients were identified. The median progression-free survival, time to treatment failure and overall survival was 3.6 (95% CI: 0.4-6.7), 3.1 (95% CI: 2.4-3.9) and 11.2 months (95% CI: 5.6-16.8) in the older group (N = 23), and 4.2 (95% CI: 3.3-5.0), 3.4 (95% CI: 3.3-5.0) and 12.2 months (95% CI: 9.1-15.4) in the younger group (N = 91), respectively. Survival curves were similar for each group, while the objective response rate was 30.4% (95% CI: 13.2-52.9%) in older patients and 35.2% (95% CI, 25.4-45.9%) for the younger group. A total of 22 older patients (95.7%) and 73 (80.2%) younger patients received primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF). Four older patients (17.3%) and 14 younger patients (15.3%) discontinued RAM+DOC due to adverse events. Conclusions: RAM+DOC is expected to be efficacious and tolerable in older patients when supported with prophylactic PEG-G-CSF therapy.

show abstract

Section: Discussionsupporting

confidence: 53%

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…At present, rhG-CSF and PEG-rhG-CSF are routinely used in antitumor adjuvant therapy, and PEG-rhG-CSF has shown more strengths. A large number of domestic and international studies have confirmed that PEG-rhG-CSF has similar efficacy to rhG-CSF but has superior safety in the prophylactic treatment of chemotherapy-induced non-myeloid-derived neutropenia [ 20 – 24 ]. RhG-CSF requires daily administration because of its short half-life [ 25 – 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…Patients treated with G-CSF had reduced all-cause mortality. Atsuto Mouri performed a retrospective study of 33 patients with non-small-cell lung cancer (NSCLC) who had previously developed FN, and 29 patients received PEG-x’rhG-CSF prophylactically at the start of the next cycle of chemotherapy [ 20 ]. The median PFS and OS times for patients treated with and without PEG-rhG-CSF prophylactically were 177 and 163 days (PFS; P = 0.20), 628 days and 274 days (OS; P = 0.13), respectively, which are similar to the results of our study.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial

et al. 2022

View full text Add to dashboard Cite

Objective To investigate pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) safety and efficacy in preventing hematological toxicity during concurrent chemoradiotherapy (CCRT) for small-cell lung cancer (SCLC). Methods We retrospectively assessed 80 SCLC patients treated with CCRT from January 2013 to December 2018 who received PEG-rhG-CSF within 48 hours after the end of chemotherapy, defined as prophylactic use, as the experimental group. An additional 80 patients who were not treated with PEG-rhG-CSF were matched 1:1 by the propensity score matching method and served as the control group. The main observations were differences in hematological toxicity, neutrophil changes, febrile neutropenia (FN) incidence and adverse reactions. Progression-free survival (PFS) and overall survival (OS) were analyzed with regular assessment and follow-up. Results The leukocyte, neutrophil, erythrocyte, and platelet counts and hemoglobin level decreased after CCRT, but the experimental group had slightly higher leukocyte and neutrophil counts than the control group (P < 0.05). The incidences of grade III-IV leukopenia (18.75% vs. 61.25%) and neutropenia (23.75% vs. 67.5%) in the experimental group were significantly lower than those in the control group (P < 0.05). The absolute neutrophil count was 4.17 ± 0.79 (× 109/L) on day 1 and peaked 6.81 ± 2.37 (× 109/L) on day 10 in the experimental group; the value in the control group was 2.81 ± 0.86 (× 109/L) on day 1. It decreased significantly and reached the minimum 0.91 ± 0.53 (× 109/L) on day 10 (P < 0.05). The experimental group had a lower FN incidence than the control group (P < 0.05). There was also no significant acute esophagitis or pulmonary toxicity. The treatment had no significant effect on PFS (11.4 months vs. 8.7 months, P = 0.958) or OS (23.9 months vs. 17.3 months, P = 0.325) over an 18.6-month median follow-up time. Conclusion PEG-rhG-CSF has good efficacy and safety in preventing hematological toxicity in SCLC patients during CCRT and has no significant effects on PFS or OS.

show abstract

“…At present, rhG-CSF and PEG-rhG-CSF are routinely used in antitumor adjuvant therapy, and PEG-rhG-CSF has shown more strengths. A large number of domestic and international studies have con rmed that PEG-rhG-CSF has similar e cacy to rhG-CSF but has superior safety in the prophylactic treatment of chemotherapy-induced non-myeloidderived neutropenia [20][21][22][23][24]. RhG-CSF requires daily administration because of its short half-life [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial

Wang

Zhu

Miao

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective To investigate pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) safety and efficacy in preventing hematological toxicity during concurrent chemoradiotherapy (CCRT) for small-cell lung cancer (SCLC). Methods We retrospectively assessed 80 SCLC patients treated with CCRT from January 2013 to December 2018 who received PEG-rhG-CSF within 48 hours after the end of chemotherapy, defined as prophylactic use, as the experimental group. An additional 80 patients who were not treated with PEG-rhG-CSF were matched 1:1 by the propensity score matching method and served as the control group. The main observations were differences in hematological toxicity, neutrophil changes, febrile neutropenia (FN) incidence and adverse reactions. Progression-free survival (PFS) and overall survival (OS) were analyzed with regular assessment and follow-up. Results The leukocyte, neutrophil, erythrocyte, and platelet counts and hemoglobin level decreased after CCRT, but the experimental group had slightly higher leukocyte and neutrophil counts than the control group (P<0.05). The incidences of grade III-IV leukopenia (18.75% vs. 61.25%) and neutropenia (23.75% vs. 67.5%) in the experimental group were significantly lower than those in the control group (P<0.05). The absolute neutrophil count was 4.17±0.79 on day 1 and peaked (6.81±2.37) on day 10 in the experimental group; the value in the control group was 2.81±0.86 on day 1. It decreased significantly and reached the minimum (0.91±0.53) on day 10 (P<0.05). The experimental group had a lower FN incidence than the control group (P<0.05). There was also no significant acute esophagitis or pulmonary toxicity. The treatment had no significant effect on PFS (11.4 vs. 8.7, P=0.958) or OS (23.9 vs. 17.3, P=0.325) over an 18.6-month median follow-up time. Conclusion PEG-rhG-CSF has good efficacy and safety in preventing hematological toxicity in SCLC patients during CCRT and has no significant effects on PFS or OS.

show abstract

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer

Cited by 12 publications

References 7 publications

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer

Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial

Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial

Contact Info

Product

Resources

About